SBIR/STTR programs will expire if Congress doesn’t reauthorize by September 30th. Senator Paul blocked reauthorization because of security problems. New provisions added to address security concerns.
Bill passed Senate, expected to pass House. SBIR/STTR programs extended for three more years.
President Biden established the National Biotechnology and Biomanufacturing Initiative to drive research and development to “Solve Our Greatest Challenges.” The Initiative’s goals strongly suggest more non-dilutive funding opportunities in grants for R&D as well as contracts related to bioproducts and biomanufacturing.
SBIR/STTR programs could expire Sept 30. Reauthorization opposed by Rand Paul and others. SBIR/STTR grants enable commercialization of federally funded research and have broad benefits that improve life for all Americans as well as billions around the globe.
President Biden established the National Biotechnology and Biomanufacturing Initiative to drive research and development to “Solve Our Greatest Challenges.” The Initiative’s goals strongly suggest more non-dilutive funding opportunities in grants for R&D as well as contracts related to bioproducts and biomanufacturing.
Since venture investment in life science companies began to slump in 2021, biopharma companies have tightened their belts notch by notch to squeeze more utility from each cent and extend their runways. In this environment, non-dilutive funding has become ever more important, especially for small and mid-sized companies.
Each $1 of non-dilutive funding from NIH translates into $8.38 of private sector investment in R&D. Companies which win non-dilutive funding from organizations such as BARDA, NIH, NSF, and CDMRP, are more likely to receive major equity investments.
Find out about more than $7 Billion In Funding Opportunities for Cancer Research – and our webinar all about them
The Peer Reviewed Cancer Research Program (PRCRP) of the Congressionally Directed Medical Research Programs (CDMRP) has just announced $130 million in funding opportunities for fiscal year 2022.
In fiscal year 2022 the Peer Reviewed Cancer Research Program (PRCRP) of the Congressionally Directed Medical Research Programs (CDMRP) will provide funds for research into cancers…
The Congressionally Directed Medical Research Programs (CDMRP) have announced their research funding opportunities for fiscal year 2022. Here’s an overview of the ALS funding opportunities. Learn more about these awards and others in our upcoming webinar, Wednesday, March 30, 2022, 1 PM (Eastern).
Website Links
Meet us at an upcoming event
- Apr122023
Cell and Gene Meeting on the Med
Barcelona, Spain
- Apr252023
London, UK
- May32023
London, UK
All Upcoming Events →
US Office
FreeMind Group
6 Liberty Square #2783
Boston, MA 02109
International Office
FreeMind Group
Hi – Tech Center
Hebrew University
Jerusalem 95702 Israel